Recombinant human thrombopoietin improves platelet engraftment after autologous hematopoietic stem cell transplantation in patients with aggressive lymphoma.
Xi QiuHuawei JiangXibin XiaoLiansheng HuangYang XuPublished in: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (2024)
rhTPO improved platelet engraftment after ASCT with aggressive lymphoma, especially the ones older than 45 years old, male, at stage-IV as diagnosed and obtained PR after previous treatment. Although rhTPO didn't lessen platelet transfusion dependence, the length and medical cost of hospitalization were reduced when rhTPO was involved. rhTPO was efficacy and safety which could be recommended after ASCT.